Alerts

Targeting Microbiota 2022 Concluding Remarks

Prof Peter C. KonturekAfter 2 years of online meetings, the 9th edition of Targeting Microbiota 2022 was successfully held in Paris, France and online from October 19th to October 21st.

Thanks to all the speakers and attendees, the congress was a great success like every year. During two days, 86+ communications were presented, with 300 attendees coming from 25 different countries.  

Read more...

Targeting Microbiota 2022 Poster Presentation Award

Gilber Skorski Poster Award 2022

This year's ISM best poster award was discerned to Gilbert Skorski, Phylogene, France for his poster entitled "Metaproteomics As A Key Approach To Identify Impacts of High Fat (HIF) Diet on the Gut Microbiome".

"The microbiomes understanding progresses depend on the available analytical tools of the meta-omics disciplines. Among those, metaproteomics is the omics which is ideally positioned at the effective functional level , not potential level, which has the power of metagenomics with the proteogenomics approach, and which detects the host and microbiome proteins simultaneously in an untargeted  way.

For the next steps, PHYLOGENE team will go on developing the metaproteomics and dedicated bioinformatics tools, including in transomics approaches, to reveal the microbiomes functions impacted in diseases or disease treatment of gut, skin, eyes, bones and cartilages and others…"

 

Targeting Microbiota 2022 Short Oral Presentation Award #2

second best short oral 2022 Abida ZahirovicShort Oral Presentation Award #2

The second ISM 2022 short oral presentation award was discerned to Abida Zahirović, Jozef Stefan Institute, Slovenia, for her talk on "Recombinant Lactic Acid Bacteria for Therapy of Inflammatory Bowel Disease".

 "My future research will be focussed on development of targeted bacterial delivery systems for anticancer agents. In my PostDoc project, I aim to engineer lactic acid bacteria to display cancer cell-specific ligand on their surface and concomitantly secrete cytotoxic protein to achieve selective killing of cancer cells. In vivo tumour-targeting bacteria can increase intratumoral accumulation of a cytotoxic protein, thus restricting its activity to the tumour and sparing healthy tissue from toxic side-effects."

Targeting Microbiota 2022 Short Oral Presentation Award #1

Oral Presentation Award Koji Hosomi

Short Oral Presentation Award #1

The first ISM 2022 short oral presentation award was discerned to Koji Hosomi, National Institutes of Biomedical Innovation, Japan for his talk on the "Unique Metabolism of Blautia Wexlerae Has Beneficial Effects on the Control of Obesity and Type 2 Diabetes"

"I would like to express my sincere thanks for such an honorable award. With this award as encouragement, I continues to vigorously research on the relationship between the microbiota and health, and hope to create academic knowledge that can contribute to improving people's health and controlling diseases."

 

 

 

 

Targeting Microbiota 2022 Scientific Contribution Award

Scientifc Award 2022 Maira Cecilia GironScientific Contribution Award

Targeting Microbiota 2022 scientific award was discerned to Maria Cecilia Giron, Università degli Studi di Padova for her strategic talk on "Cancer Therapy and Microbiota".

Prof. M. Cecilia Giron gave an overview of the influence of gut microbiota on ensuring the efficacy and lowering the toxicity of current cancer therapies. She is Associate Professor of Pharmacology at the University of Padova where together with her team is focused in targeting the interaction between innate immunity, enteric nervous system and microbiome in diverse intestinal inflammatory pathologies (e.g., Irritable Bowel Syndrome (IBS), Inflammatory Bowel Diseases (IBD) and Inflammation-Associated Colorectal Cancers) as well as in gut neuropathies including Multiple Sclerosis and Parkinson’s Disease in order to develop new pharmacological treatments and/or nutritional strategies.

She currently serves as pharmacologist in the Ethics Committee for Clinical Studies of the Padova University Hospital, in the Ethics Committee for Oncological Clinical Trials of the Veneto Institute of Oncology and in the Veneto Region Medicines Evaluation Committee. She is a pioneer in research on the role of gut microbiota and intestinal function in normal and pathological conditions. She is author of more than 60 peer-reviewed publications, and co-founder of Eubiome, an innovative University spin-off and start-up, involved in FMT research and therapeutic applications of gut microbiota in human and animal recipients.

Targeting Microbiota 2022 Congress
October 19-21, 2022- Paris, France
www.microbiota-site.com

Targeting Microbiota 2022 Highlights

WhatsApp Image 2022 07 28 at 4.58.41 PM

The 9th ISM Annual Meeting will take place from the 19th to the 21st of October in Paris, France and Online. More than 300 participants from 25 different countries will be attending, and more than 86 communications will be presented this year.

Dr. Marvin Edeas, Founder & Chairman of ISM, Institut Cochin, INSERM, Université de Paris, France, stated: “We will be back this year in person in Paris after 2 years, with more diversity of topics which may explain the complexity of our microbiota”.

Dr. Edeas thinks that we are still at the beginning in our exploration and we probably need to desiccate more the mechanism behind microbiota efficacy such as: extracellular vesicles and exosomes and their impact on microbiota communication and microbiota-host relationship, along with their potential implication in disease. Further explore the role of microbiota and its metabolites on iron metabolism should be highlighted.

Targeting Microbiota 2022 will highlight many new topics: Oral microbiota, vaginal microbiota, skin microbiota, metabolites, microbiota biofilms, retinal disorders, respiratory infections, arterial thrombosis, ischemic stroke, ageing, circadian system, depression, FMT, multi-omics, gene editing, precision medicine, cancer immunotherapy, mineral water, Mediterranean diet, weight loss...

Abstract Submission

  • Short Oral Presentation submission deadline: September 30
  • Poster Presentation submission deadline: October 7

More details on abstract submission

Registration

You can choose whether to register for in-person or online participation. Registration details.

If you need more information don't hesitate to contact us.

FMT 2022: Reorganization and Perspective

Prof Peter C. Konturek

Prof. Peter C. Konturek, President of ISM from  Teaching Hospital of the University of Jena, Germany will present a talk entitled "FMT 2022: Reorganization and Perspective".

Prof. Konturek will present new data on FMT and include important remarks on the reorganization of fecal microbiota therapy due to the SARS Cov2 Pandemic.

 

Targeting Microbiota 2022 Congress
October 19-21, 2022- Paris, France
www.microbiota-site.com

Microbiota and Drug Metabolism: Towards a Personalized Medicine

Microbiota 2022 Dr. Cristina Giaron 2Dr. Cristina Giaroni from University of Insubria, Italy will be joining us this October to moderate a session entitled "Microbiota and Drug Metabolism: Towards a Personalized Medicine". 

The gut microbiota plays a pivotal role in human health by modulating gut epithelial and immune cell functions, preventing pathogen colonization, and providing essential nutrients and bioactive metabolites. From a metabolic standpoint, gut microbes actively participate to drug metabolism, influencing drug disposition, half-life, and efficacy. Gut bacteria are not only a major source for local drug metabolism but can also indirectly affect xenobiotic stability by modulating host-mediated metabolic clearance as well as by competition of bacterial-derived metabolites for host drug metabolic pathways.

In view of the existing bidirectional drug-microbiota relationship, drugs themselves can influence the composition and function of the gut microbiota. In this context, alterations of the gut microbiota homeostasis after broad spectrum antibiotic administration does not only deprive the host from essential bacterial metabolites but may also profoundly alter drug metabolic pathways. A further critical issue is the development of antibiotic resistance in some species of bacteria. The human gut is considered the main reservoir of antibiotic resistance genes. Antibiotic treatment may rapidly increase the pool of resistance genes, favouring the formation of a biofilm rich of microorganisms resistant against several antibiotics thus contributing to reduce host defence and hampering the efficacy of treatments for bacterial infections.

Overall, these considerations open a new avenue for a research aiming at evaluating the relevance of drug-gut microbiota interplay in the variation of individual responses to disease treatment, thus opening the possibility for more personalized therapeutic approaches.

Join us in Targeting Microbiota 2022 and benefit from the experience of Dr. Giaroni. Don't forget that you can share you work in this session by submitting your abstract.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

 

Fecal Microbiota Transplantation as an Immunomodulatory and Anti-Infective Agent

Microbiota 2022 Congress speaker Jarosław BilinskDr. Jarosław Biliński, from Medical University of Warsaw, Poland will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Fecal Microbiota Transplantation as an Immunomodulatory and Anti-Infective Agent".

There is mounting evidence that the gut microbiome directly influences immune responses, especially in patients with hematological malignancies undergoing hematopoietic cell transplantation. Recent studies show that fecal microbiota transplantation could decrease the number of infectious complications, decolonize the gut from antibiotic-resistant bacteria and even treat immune complications like graft-versus-host disease. More attention is paid to the prophylactic use of microbiota modulation in most affected patients, which could revolutionize current practices.

Join Dr. Biliński in Targeting Microbiota 2022 to benefit from his experience and better understand microbiota immunotherapy.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Gene Editing and Microbiome Therapy

Nahla MansourProf. Nahla Mansour, National Research Center, Egypt, will be joining us this October to discuss her latest findings on "Gene Editing and Microbiome Therapy". 

Gene editing holds a promising future in microbiome therapy and exploring the complex interplay between members of the microbiome and our bodies. 

In this presentation, Dr. Mansour will highlight the re-emerging of gene editing tools and multiple strategies in microbiome therapy past, present, and future. 

She will show her previous work describing the genetically engineered probiotic strains that have been constructed by our group and also our new project using CRISPR- Cas tools.

A whole session will be dedicated to the Strategies, Innovations & Challenges to Target Microbiota Dysbiosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

May the Microbiota of the long-lived Naked Mole-rat Affect Human Health?

Microbiota 2022 Speaker Prof. Dr. med. Gerd Birkenmeier

Porf.  Gerd Birkenmeier from University of Leipzig, Germany will join the Targeting Microbiota 2022 Congress and give a presentation entitled "May the Microbiota of the long-lived Naked Mole-rat Affect Human Health?.

Join Prof. Birkenmeier in Targeting Microbiota 2022 to benefit from his experience on the host - microbiota interactions.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Cancer therapy and Microbiota

Microbiota 2022 Congress speaker Maria Cecilia GironDr. Maria Cecilia Giron, from University of Padova, Italy will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Cancer therapy and Microbiota".

Join Dr. Giron in Targeting Microbiota 2022 to benefit from his experience and better understand the role of microbiota in arterial thrombosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Interactions of Skin Microbiota with Chosen Plant Extracts and Natural Products

Microbiota 2022 Speakers 11Dr. Sebastian Granica, Medical University of Warsaw, Poland, will be joining the 9th ISM Annual Meeting to discuss the "Interactions of Skin Microbiota with Chosen Plant Extracts and Natural Products". 

Join Targeting Microbiota 2022 to lear more about the skin microbiota. Secure a place.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Gut Microbiome and Retinal Disorders: Recent Advances and Perspectives

Microbiota 2022 Speakers 9Dr. Dimitra Skondra, University of Chicago, USA, will be joining the 9th ISM Annual Meeting to discuss "Gut Microbiome and Retinal Disorders: Recent Advances and Perspectives".

Recent work demonstrates important role of gut microbiome and retinal diseases such as age-related macular degeneration and retinopathy of prematurity. Emerging evidence for the existence and pathways of gut-retina axis can elucidate previously unknown pathways involved in retinal diseases and also presents an exciting potential therapeutic avenue. This talk aims to provide an update on recent advances in the current knowledge on the relationship between the gut microbiome and retinal disorders.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

 

Vaginal Microbiota and Dysbiosis: Recent Advances and Perspective

Microbiota 2022 Speakers Gary VentoliniProf. Gary Ventolini, Texas Tech University Health Sciences Center, USA, will be joining the 9th ISM Annual Meeting to discuss the Recent Advances and Perspectives on Vaginal Microbiota and Dysbiosis. 

Trillions of bacteria colonize the human body and 9% are found in the female genital tract: vulva, vagina, cervix/uterus and adnexa. Vaginal microbiota influence from conception to birth has only been unbent during the last decade.

This presentation will appraise the vaginal microbiota, will review changes taking place during dysbiosis, and will update on current advances and outlooks regarding the impact on human reproduction. 

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbiota & Microbiotal Medicine: Where We are Now & What’s Next?

Microbiota 2022 Speakers 1

Dr. Marvin Edeas, Founder & Chairman of ISM, Institut Cochin, INSERM, Université de Paris, France, will introduce the 9th Targeting Microbiota meeting and he will talk about "Microbiota & Microbiotal Medicine: Where We are Now & What’s Next?".

The aim of Dr. Marvin Edeas is to introduce a new way of thinking about the medicine of tomorrow. He will initiate the reflection and discussion about strategies which will allow us to accelerate Microbiotal medicine.

Dr. Marvin Edeas will try to discuss:

- Why we failed to treat many diseases?

- Do we need to dedicate a specific treatment to one specific organ or specific pathology?

Dr. Marvin Edeas believes that the medicine of tomorrow will connect all organs together and with our microbiota and microbiome. All therapeutic strategies will come through the way we will take into consideration the quality of Microbiota and metabolites, signaling pathways, epigenetic and more.

Dr. Edeas thinks that we are still at the beginning in our exploration and we probably need to desiccate more the mechanism behind microbiota efficacy such as: extracellular vesicles and exosomes and their impact on microbiota communication and microbiota-host relationship, along with their potential implication in disease. Further explore the role of microbiota and its metabolites on iron metabolism should be highlighted.

He will discuss the 4 main axes that should be exploreed in the furture:

  1. Olfactory receptors;
  2. Brain and behaviour;
  3. Ageing & longevity;
  4. Artificial intelligence and algorithms.

 

Reference: Microbiota medicine: towards clinical revolution - BMC Journal of Translational Medicine

Join Targeting Microbiota 2022 to learn more about the future of microbiotal medicine.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

A Gut Commensal, Parabacteroides distasonis, and Type 1 Diabetes Onset

Targeting Microbiota 2022 Emrah AltindisDr. Emrah Altindis, from the Biology Department Boston College, USA, will be joining us this October to discuss his latest findings on the "A Gut Commensal, Parabacteroides distasonis, and Type 1 Diabetes Onset". 

Type 1 Diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic β-cells. One of the earliest aspects of this process is development of autoantibodies and T-cells directed at an epitope in the B-chain of insulin (insB:9-23). Analysis of microbial protein sequences with homology to insB:9-23 sequence revealed 17 peptides showing >50% identity to insB:9-23. Of these, one peptide, found in the normal human gut commensal Parabacteroides distasonis, activated both human T cell clones from T1D patients and T-cell hybridomas from non-obese diabetic (NOD) mice specific to insB:9-23. Immunization of NOD mice with P. distasonis insB:9-23 peptide mimic or insB:9-23 peptide verified immune cross-reactivity. Colonization of female NOD mice with P. distasonis accelerated the development of T1D, increasing macrophages, dendritic cells and destructive CD8+ T-cells, while decreasing FoxP3+ regulatory T-cells. Western blot analysis identified P. distasonis reacting antibodies in sera of NOD mice colonized with P. distasonis and human T1D patients. Furthermore, adoptive transfer of splenocytes from P. distasonis treated mice to NOD/SCID mice enhanced disease phenotype in the recipients. Finally, analysis of human infant gut microbiome data revealed that exposure of infants to P. distasonis may modulate disease pathogenesis. Taken together, these data demonstrate the potential role for an insB:9-23-mimimetic peptide from gut microbiota as a molecular trigger or modifier of T1D pathogenesis.

Join Dr. Altindis in Targeting Microbiota 2022 to benefit from his experience and better understand the relationship between gut commensals and diabetes onset.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Influence of the Gut Microbiome in Ischemic Stroke Risk and Ischemic Stroke Outcome

Microbiota 2022 Speakers Miquel LledósDr. Miquel Lledós from the Biomedical Research Institute Sant Pau, Spain will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Influence of the Gut Microbiome in Ischemic Stroke Risk and Ischemic Stroke Outcome".

We performed shotgun metagenomics sequencing to analyse the taxonomic profiles in ischemic stroke patients. We aimed to identify microbiota taxa associated with: risk of ischemic stroke, neurological outcome in the acute phase at 6h and 24h (classified with the National Institute of Health Stroke Scale (NIHSS) as mild, moderate or severe stroke), and functional outcome at 3 months measured with the modified Rankin Scale (mRS). We found multiple new taxonomic profiles associated with stroke, revealing that gut microbiome could be an important factor associated with stroke risk and stroke acute and long-term outcome.

Join Dr. Lledós in Targeting Microbiota 2022 to benefit from his experience and expand your knowledge about the link between the microbiota and stroke.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Interactions Between Epithelial Proteases And Gut Microbiota Biofilms During Intestinal Disease

Jean Paul Motta Microbiota 2022 Speakers 15Dr. Jean-Paul Motta, Institute of Digestive Health Research, France, will join Targeting Microbiota this October to present his new studies on the "Interactions Between Epithelial Proteases And Gut Microbiota Biofilms During Intestinal Disease". 

Dr. Motta states that Inflammatory Bowel Disease (IBD) is linked with abnormal upregulation of epithelial protease, such as elastase and thrombin. Their recent works aim to decipher the mechanisms by which such high protease activity could fuel intestinal inflammation via an action on host receptors, but also to directly alter commensal microbiota forming biofilms at the mucosal surface. 

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Host / Microbiota Interaction at the Mucosal Surface – Importance of a No Man’s Land !

Dr. Benoit ChassaingDr. Benoit Chassaing from Institut Cochin, France will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Host / Microbiota Interaction at the Mucosal Surface – Importance of a No Man’s Land !".

Recent researches have highlighted the importance of a proper host-microbiota interaction at the mucosal surface, with the observation of microbiota encroachment within the normally sterile mucus layer in preclinical models of chronic inflammatory diseases as well as in humans suffering IBD or type 2 diabetes.

Dr. Chassaing's presentation will discuss dietary factors involved in the promotion of microbiota encroachment, as well as mechanisms by which targeted immunization can be used to prevent / reverse encroachment and hence protect against chronic inflammatory diseases.

Join Dr. Chassaing in Targeting Microbiota 2022 to benefit from his experience on the host - microbiota interactions.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Host-Microbes Mechanisms during E. coli Infections and Diet-induced Dysmetabolism

Microbiota 2022 Speakers

Dr. Matteo Serino, CRCN researcher from INSERM (France), will be joining us this October to present a talk entitled "Host-Microbes Mechanisms during E. coli Infections and Diet-induced Dysmetabolism".

A high-fat diet-induced gut microbiota dysbiosis is at the carrefour between E. coli infections and metabolic diseases such as obesity and type 2 diabetes. Dr. Serino will discuss about both cellular and molecular mechanisms governing dysbiosis-induced systemic, gut and hepatic inflammation in lean and obese mice.

These mechanisms include: i) platelets modulation as sentinels of E. coli-induced systemic inflammation; ii) NLRP3 inflammasome activation to control gut inflammation and iii) modulation of hepatic microRNAs as bridge molecules between gut microbes and hepatic inflammation.

Join us in Targeting Microbiota 2022 and benefit from the experience of Dr. Serino. Don't forget that you can share your work in this session by submitting your abstract.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next